

Phi Pharma SA announces closing of CHF 3.7 million series A financing

December 20, 2016, Geneva, Switzerland. Phi Pharma SA, a Swiss biotherapeutics company developing peptide drug conjugates as targeted drugs in oncology, auto-immune disease and infectious disease, announced the closing of a CHF 3.7m Series A financing, led by an undisclosed investor.

The company has assembled a group of successful entrepreneurs and investors from the biotech industry, including early backers of Swiss biotech companies such as Actelion, Axovan, Molecular Partners, Kuros and Novimmune.

The financing will allow Phi Pharma to demonstrate *ex-vivo* efficacy in patient derived tumour cells and select the optimal clinical candidate to take forward into clinical trials in the first oncology indication.

CEO Tom Shepherd recently joined the company, bringing decades of experience in building development stage biotech start-ups in the UK, France and the USA. He commented about the opportunity ahead: “the current financing, which closed above our initial target, amply provides the resources we need to reach important value-inflection milestones in 2017”.

In describing the Phi team, he added “as a young company with a deliberately restricted media profile, we are delighted to have been able to assemble such an outstanding group of world-class scientists, entrepreneurs and investors who have extensive experience in developing globally recognised therapeutics and building successful biotech companies”.

About Phi Pharma

Phi Pharma SA is a private Swiss-based biopharmaceutical company. It specializes in the discovery and early development of peptide drug conjugates for improving the treatment of diseases with high unmet medical needs. The Phi Pharma technology is based on a powerful new class of peptide drug conjugates with specific cellular targeting and efficient intra-cellular delivery. The lead programs are in oncology and infectious diseases.

Media Contact:

Dr Tom Shepherd, Chief Executive Officer

Email: tom.shepherd@phi-pharma.com

info@phi-pharma.com

Web: <http://www.phi-pharma.com>